In order to assess whether phosphoproteomicscould also be used to classify cells according to their responses to kinase inhibitor treatment, we compared phosphorylation patterns with the sensitivity of a panel of seven AML cell lines (Additional file 1, Table S2) to a PI3K/mTOR inhibitor (PI-103), a MEK-inhibitor (MEK-i), and a JAK-inhibitor (JAK-i). The gene discussed is MAP2K7; the disease is acute myeloid leukemia.